新技术为改善患者护理提供了巨大的可能性，但不同欧洲国家的采用情况各不相同。为了成功整合这些进步，至关重要的是优先考虑患者利益，避免因寻求维持既定立场或忽视合作的问题而偏离轨道。癌症患者的下一代测序和液体活检在早期诊断和减少痛苦方面具有巨大潜力，但前提是它们能够有效地应用于常规医疗保健中。对欧洲成员国的基础设施和治理要求进行了检查，以确定显着差距以及利用这些技术所带来的好处的准备程度方面存在差异。这些差异凸显了欧盟 (EU) 内部现有的不平等和错失的机会，而不同的经济状况进一步加剧了这种情况。随着 2024 年至 2025 年的卫生政策和公共支出的发展，现在是优先考虑确保患者能够获得技术和科学进步的最佳时机。版权所有 © 2024 作者。由爱思唯尔有限公司出版。保留所有权利。

Novel technologies offer great possibilities for improving patient care, but their adoption varies across different European countries. To successfully integrate these advancements, it is crucial to prioritize patient interests and avoid getting side-tracked by issues that seek to preserve established positions or neglect collaboration. Next-generation sequencing and liquid biopsy in cancer patients hold substantial potential for early diagnosis and reducing suffering, but only if they are effectively implemented into routine health care.An examination of the infrastructure and governance requirements in European member states was conducted to identify significant gaps and discrepancies in the readiness to capitalize on the benefits that these technologies can provide.These disparities highlight the existing inequalities and missed opportunities within the European Union (EU), which are further exacerbated by varying economic statuses.As Europe undergoes a comprehensive review of its health policies and public spending between 2024 and 2025, it is an opportune time to prioritize ensuring that patients can access the advancements offered by technology and science.Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.